Glenmark Pharmaceuticals Limited has informed the Exchange about Presentation
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals shared its Investor Day 2025 presentation in Mumbai, outlining the 'Glenmark 3.0' growth strategy across three phases through 2030 and beyond, focused on Dermatology, Respiratory, and Oncology. The company disclosed medium-term financial targets: 12-14% revenue CAGR, consolidated EBITDA margin moving up to 23% (from FY26), 20% ROCE and ROE, R&D spend at 7-7.5% of revenue, and annual capex of ~₹8,000 crore. Key highlight was the AbbVie licensing deal for ISB 2001 (a trispecific antibody for multiple myeloma) worth US$1.925 billion total, including US$700 million upfront, with IGI expected to generate US$70 million annually for Glenmark. IGI is being positioned for a future IPO and is set to become self-sustaining. R&D-to-revenue ratio dropped from 9.2% to 7.0% (FY24 to FY25), and capex fell from ~₹8,984 crore to ~₹7,496 crore.
Positive for shareholders - the company laid out a clear multi-year roadmap with improved profitability targets (23% EBITDA margin), reduced R&D burden via the IGI self-sustaining model, and a large potential windfall from the AbbVie deal. The 12-14% growth guidance and 20%+ return ratio targets could support stock re-rating if execution stays on track.